General Dermatology

Dermatology Times is looking back on the top stories in dermatology from the month of April.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress, including laughter yoga, relationships, and mindset shifts

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress — from family time and fitness to emotional intelligence training and even Botox.

Learn more about the in-depth topics covered in the April 2026 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

A systematic review of 8 studies finds early evidence for microneedling plus exosome therapy across alopecia, aging, pigmentation, and scarring, but calls for larger trials.

The deal would vault the combined company to 7th-largest biosimilar player globally, with direct implications for biologic access in dermatology.

Combination therapy may be particularly beneficial for frontal hairline regrowth, a traditionally difficult area to treat.

The FDA has accepted the resubmitted BLA for relabotulinumtoxinA, a next-generation neuromodulator for treating facial lines in adults.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the approval of dupilumab for pediatric CSU, phase 2b hair growth results with rezpegaldesleukin, multispecific biologics for AD, and more.

At the 2026 Winter Clinical Miami meeting, dermatology leaders emphasized that thriving careers require skills beyond clinical expertise.

Renal transplant patients face frequent warts, fungal infections, and steroid acne, according to new 10-year data.

Although microbes inhabit many body sites, the skin is one of the most densely populated areas after the gastrointestinal tract.

A meta-analysis cited in the review found depression prevalence among melasma patients at 43.4% — approximately 12 times the estimated global rate — highlighting the psychiatric weight of pregnancy-associated skin changes.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on delgocitinib sNDA for pediatric CHE, new 12-month data for clascoterone 5% in androgenetic alopecia, the rise of GLP-1 usage in dermatology, and more.

Kathleen Moe, MD, offers guidance on creating 5-star dermatology patient experience systems for faster access, consistent scripts, and guided checkout that reduce callbacks and build trust.

Dysregulation of the innate immune system, inflammatory cytokines, and abnormal blood vessel growth plays a key role in persistent redness and flushing.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

A new case-control study found that patients with pemphigus vulgaris and bullous pemphigoid face more than twice the odds of comorbid acute stress disorder compared with matched controls.

Many participants in the mobile screening program have never previously seen a dermatologist.

In this episode, Daniel Walker, MD, FAAD, explains how GLP-1 drugs may be effective for psoriasis and HS, linking skin inflammation with weight and heart health.

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.